Business
AstraZeneca Launches $1.5 Billion Savings Plan to Fund Drug Pipeline
Adrià Calatayud·Wall Street Journal·October 30, 2026
The U.K. drugmaker benefited from strong sales of cancer drugs that offset the effect of patent expirations and lifted the group’s top line.
Read the full story at Wall Street Journal →